| Document Date: 2015-04-20 15:25:49
Open Document File Size: 401,80 KBShare Result on Facebook
City Windward Parkway Alpharetta / Alpharetta / / Company Alimera Sciences Inc. / Ames / ITT / / Event FDA Phase / / IndustryTerm chemical name / chemical structure / / MedicalCondition Glaucoma / Photophobia / scar / Optic atrophy / Pneumonia / viral infection / Includes cataract / Cataracts / Headache / subsequent cataract / secondary ocular infections / Periocular Infections ILUVIEN / Carcinogenesis / endophthalmitis / Hypersensitivity ILUVIEN / herpes / active epithelial herpes simplex keratitis / posterior subcapsular cataracts / Eye irritation / viral disease / dendritic keratitis / Conjunctivitis / eye inflammation / periocular infections / Eye pain / diabetic macular edema / ocular herpes / retinal detachments / Hypersensitivity / Renal Failure / vaccinia / inflammation / Vitreous detachment / inflammatory responses / Non-ocular Anemia / cataract / varicella / mycobacterial infections / fungal diseases / secondary ocular infection / / MedicalTreatment drug delivery system / retreatment / surgery / cataract surgery / / Organization DOSAGE AND ADMINISTRATION / FDA / / / Position optic nerve head / General / assistant / / Product Intravitreal Injection / fluocinolone acetonide / Intravitreal injections / For Intravitreal Injection / Intravitreal Injection-related Effects Intravitreal injections / Posterior capsule / Any IOP-lowering medication / ILUVIEN / containing 0.19 mg of the active ingredient fluocinolone acetonide / / ProvinceOrState Georgia / / PublishedMedium Baseline / / Technology Pharmacokinetics / laser / drug delivery system / / URL www.fda.gov/medwatch / www.alimerasciences.com / /
SocialTag |
2.2 Administration 5.3 Risk of Implant Migration These highlights do not include all the information needed to use ILUVIEN® safely and effectively. See full prescribing information for ILUVIEN.